MARKET

VRAY

VRAY

ViewRay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.700
+0.050
+1.37%
After Hours: 3.650 -0.05 -1.35% 16:10 12/04 EST
OPEN
3.680
PREV CLOSE
3.650
HIGH
3.744
LOW
3.560
VOLUME
1.73M
TURNOVER
--
52 WEEK HIGH
4.660
52 WEEK LOW
1.106
MARKET CAP
549.45M
P/E (TTM)
-4.2983
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ViewRay to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
, /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
PR Newswire - PRF · 11/23 13:00
ViewRay to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
PR Newswire · 11/23 13:00
The President of ViewRay, Inc. (NASDAQ:VRAY), Scott Drake, Just Bought 81% More Shares
Potential ViewRay, Inc. (NASDAQ:VRAY) shareholders may wish to note that the President, Scott Drake, recently bought...
Simply Wall St. · 11/16 14:01
ViewRay +10.6% on CEO acquiring shares
ViewRay ([[VRAY]] +10.6%) president & CEO Drake Scott William acquired an aggregate 155K shares at an average price of $3.2252 for total transaction value of $490K.Press Release
Seekingalpha · 11/12 19:34
ViewRay CEO Drake Purchased 155,000 Shares @ Avg Price $3.23/Share
-Form 4
Benzinga · 11/12 13:28
Amsterdam University Medical Centers Treats 1,000th Patient with MRIdian SMART MRI-Guided Radiation Therapy
, /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand patients using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy). Amsterdam UMC continues to advance the practice of high-dose ablative radiation therapy with MRIdian through research and publication of the center's findings.
PR Newswire - PRF · 11/12 11:30
Amsterdam University Medical Centers Treats 1,000th Patient with MRIdian SMART MRI-Guided Radiation Therapy
ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand patients using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy). Amsterdam UMC continues to advance the practice of high-dose ablative radiation therapy with MRIdian through research and publication of the center's findings.
PR Newswire · 11/12 11:30
Leading Academic Clinical Training Hospital, Universitair Ziekenhuis Brussels, Purchases ViewRay's MRIdian Linac
, /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Universitair Ziekenhuis Brussels has purchased a MRIdian Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.
PR Newswire - PRF · 11/10 11:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRAY. Analyze the recent business situations of ViewRay through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRAY stock price target is 3.833 with a high estimate of 5.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 211
Institutional Holdings: 168.89M
% Owned: 113.73%
Shares Outstanding: 148.50M
TypeInstitutionsShares
Increased
24
5.20M
New
31
-673.59K
Decreased
46
6.65M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.02%
Healthcare Equipment & Supplies
+1.26%
Key Executives
Chairman/Independent Director
Daniel Moore
President/Chief Executive Officer/Director
Scott Drake
Chief Financial Officer
Brian Knaley
Chief Financial Officer
Zachary Stassen
Chief Operating Officer
Shahriar Matin
Chief Scientific Officer
James Dempsey
Independent Director
Caley Castelein
Independent Director
D. Keith Grossman
Independent Director
Scott Huennekens
Independent Director
B. Kristine Johnson
Independent Director
Brian Roberts
Independent Director
Gail Wilensky
Independent Director
Kevin Xie
Independent Director
Ted Wang
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VRAY
ViewRay Inc. designs, manufactures and markets the ViewRay MRIdian. The MRIdian is a system that integrates high quality radiation therapy with simultaneous magnetic resonance imaging (MRI). It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. The MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRIdian also records the level of radiation dose that the treatment area has received. MRIdian system is comprised of three components: the MRI system, the radiation delivery system and an integrated treatment planning and delivery software. The MRI system is the component of MRIdian that captures soft tissue images of the patient’s body. Its MRI system captures and displays live images in one plane, four times per second or in three planes, two times per second.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Viewray Inc stock information, including NASDAQ:VRAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRAY stock methods without spending real money on the virtual paper trading platform.